Navigation Links
Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- Accera Inc. announced today that topline data from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) will be presented at the annual meeting of the American Academy of Neurology (AAN) in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

Accera's vice president of clinical development Dr. Lauren Costantini will present the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session on Tuesday, May 1 at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The randomized, double-blinded, placebo-controlled Phase II trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Subjects visited the clinic on five occasions during the study to have their memory and other symptoms evaluated. Treatment lasted for three months and following a two-week washout, all subjects who had completed the three-month study were given the opportunity to participate in an open-label extension study. The open-label data will be presented at the Alzheimer's Association's International Prevention Conference in Washington, DC in early June.

About AC-1202

AC-1202 is an orally available, liquid compound that has been shown in preclinical studies to prevent the massive brain cell death seen in AD and other neurodegenerative diseases. Brain imaging techniques performed on AD patients reveal a decreased uptake of glucose, the brain's preferred source of energy. Efficiently converted by the liver into ketones, AC-1202 preserves the glucose-deprived brain cells with an alternative energy source. The potentially neuroprotective mechanism of AC-1202 is also being evaluated in age-associated memory impairment, Parkinson's disease, F riedrich's ataxia, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. www.accerapharma.com

    For information contact:

    Meghan Feeks

    Richard Lewis Communications, Inc.

    212-827-0020

    

mfeeks@rlcinc.com

CONTACT: Meghan Feeks of Richard Lewis Communications, Inc.,+1-212-827-0020, or , for Accera, Inc. mfeeks@rlcinc.com

Web site: http://www.accerapharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 15, 2017  Amy Baxter MD, chief executive officer ... noninvasive pain relief, was awarded a 2017 Top 40 ... was recognized at the MM&M Top 40 Healthcare Transformers ... on May 10, 2017. The dinner followed ... go "beyond the pill."  "Innovation goes beyond ...
(Date:5/12/2017)... May 12, 2017  The China and Canada ... that consumes less water, energy and detergent, and features a powerful ... LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s panties ... ... is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... , ... An inventor from Columbia, S.C., wants to offer people with manual ... in a firework accident, so she couldn’t grip a pen properly," he said. "This ... designed and created a prototype for the HELPEN HAND, a special pen that enables ...
(Date:5/22/2017)... Galena, Alaska (PRWEB) , ... May 22, 2017 , ... ... town near the Arctic Circle made big headlines when it was targeted to build ... Low-Cost Energy in Bush Alaska,” former city manager Marvin L. Yoder describes the journey ...
(Date:5/22/2017)... Francisco, CA (PRWEB) , ... May 22, 2017 ... ... will sponsor a program on Wellocity to empower WeightZone Factor members to ... their medications, and get an excellent health education, all on their mobile phones. ...
(Date:5/21/2017)... NY (PRWEB) , ... May 19, 2017 , ... Chris Cornell, 52, was found dead ... imagine why one of the most respected lead singers in the rock industry would take ... history of mental illness. FindaTopDoc investigates how mental illness played a role in the death ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... between ABC Financial Services and financial systems. , Dozens of clubs ... files that are electronically processed through GetLinked into their club’s accounting system , ...
Breaking Medicine News(10 mins):